Logo

Sanofi and Regeneron to Initiate the Clinical Program Evaluating Kevzara (sarilumab) in Patients with Severe COVID-19

Share this

Sanofi and Regeneron to Initiate the Clinical Program Evaluating Kevzara (sarilumab) in Patients with Severe COVID-19

Shots:

  • The P-II/III study will assess the safety & efficacy Kevzara + supportive care vs PBO + supportive care in ~400 patients in a ratio (2:2:1) hospitalized with serious complications from COVID-19
  • The study is designed into two parts:  First part will evaluate the impact of Kevzara on fever and patients' need for supplemental oxygen while the second part will evaluate the improvement in longer-term outcomes including preventing death & reducing the need for mechanical ventilation- supplemental oxygen and/or hospitalization
  • Kevzara is a mAb inhibiting IL-6 pathway by targeting the IL-6 receptor. The companies will continue to collaborate on COVID-19 and other ARDS development- with Regeneron leading US studies and Sanofi leading ex-US studies. In 2019- the companies intend to simplify the joint collaboration for Kevzara- which is expected to be finalized in the Q1’20

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Pharmaceutical Technolog


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions